Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study

Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study

Summary: Background: People with end-stage kidney disease, including people on haemodialysis, are susceptible to greater COVID-19 related morbidity and mortality. This study compares the immunogenicity and clinical effectiveness of BNT162B2 versus ChAdOx1 in haemodialysis patients. Methods: In this...

Full description

Bibliographic Details
Main Authors: Paul Martin, Sarah Gleeson, Candice L. Clarke, Tina Thomson, Helena Edwards, Katrina Spensley, Paige Mortimer, Stacey McIntyre, Alison Cox, Graham Pickard, Liz Lightstone, David Thomas, Stephen P. McAdoo, Peter Kelleher, Maria Prendecki, Michelle Willicombe
Format: Article
Language:English
Published: Elsevier 2022-10-01
Series:The Lancet Regional Health. Europe
Subjects:
COVID-19
Vaccines
Effectiveness
End stage kidney disease
Haemodialysis
Immunosuppression
Online Access:http://www.sciencedirect.com/science/article/pii/S2666776222001740

Internet

http://www.sciencedirect.com/science/article/pii/S2666776222001740

Similar Items